FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> Neupro | Schwarz BioSciences

Neupro - 2007 FDA approvals

Tools

Drug: Neupro (rotigotine)
Indication: Parkinson's
Company: Schwarz BioSciences
Approval Date: May 9, 2007

Scoop: Neupro is a non-ergot dopamine agonist skin patch designed to treat symptoms of early Parkinson's disease. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease. Rotigotine was approved by the EMEA in 2006.

More News:
Schwarz Pharma wins OK for Parkinson's patch. Report
Schwarz seeks new approval for Neupro. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Neupro   Schwarz BioSciences